OKYO

OKYO Pharma Limited

1.43

Jul 17 • 03:51PM ET +0.05 (3.62%)

1.43

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Biotechnology United Kingdom Micro NASD

Peers: ANIX ATYR COYA CYPH INO LONA NRXS CGTX NRXP KALA

Scroll to Statements

Index	-
Market Cap	73.46M
Enterprise Value	69.43M
Income	-4.61M
Sales	0.00M
Book/sh	-0.09
Cash/sh	0.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	May 17, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	17.41
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.58
Current Ratio	0.58
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.13
EPS next Y	-0.15
EPS next Q	-0.03
EPS this Y	-15.38%
EPS next Y	0.00%
EPS next 5Y	-
EPS past 3/5Y	-178.81% -114.91%
Sales past 3/5Y	- -
EPS Y/Y TTM	-1771.64%
Sales Y/Y TTM	-
EPS Q/Q	13.41%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	85.71% -

Insider Own	32.56%
Insider Trans	0.00%
Inst Own	20.33%
Inst Trans	67.77%
ROA	-123.47%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.60%
SMA50	-10.47%
SMA200	-24.20%
Trades

Shs Outstand	38.45M
Shs Float	34.64M
Short Float	0.09%
Short Ratio	0.39
Short Interest	0.03M
52W High	3.35 -57.30%
52W Low	1.34 6.71%
Volatility	8.72% 6.59%
ATR (14)	0.11
RSI (14)	39.97
Beta	0.07
Rel Volume	0.35
Avg Volume	82.21K
Volume	28,693

Perf Week	-15.38%
Perf Month	-4.67%
Perf Quarter	-10.06%
Perf Half Y	-49.47%
Perf YTD	-30.92%
Perf Year	-50.69%
Perf 3Y	20.17%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	9.00
Prev Close	1.38
Price	1.43
Change	3.62%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-26	Initiated	Piper Sandler	Overweight	$7
Dec-08-25	Initiated	B. Riley Securities	Buy	$5

Jul-11-26 10:00AM	OKYO Pharma advances toward Phase 3 FDA trial - ICYMI (Proactive)
Jul-08-26 08:33AM	OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain (Proactive) -5.14%
08:12AM	Nasdaq bucks market selloff as US-Iran tensions push oil higher (Proactive)
08:12AM	Dow and Nasdaq lose more ground as Trump says Iran ceasefire 'over' (Proactive)
07:00AM	OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain (GlobeNewswire)
11:18AM	Loading…
Jul-07-26 11:18AM	OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain (Proactive) +8.70%
07:00AM	OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium (GlobeNewswire)
May-23-26 08:00AM	OKYO Pharma expands scientific advisory board with cornea expert - ICYMI (Proactive)
May-19-26 11:02AM	OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment (Proactive)
09:58AM	OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board (Proactive)
07:00AM	OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD (GlobeNewswire)
Apr-29-26 07:00AM	OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May (GlobeNewswire)
Apr-07-26 08:40AM	OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026 (Proactive)
08:40AM	OKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentation (Proactive)
07:00AM	OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting (GlobeNewswire)
12:00PM	Loading…
Mar-19-26 12:00PM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire)
10:00AM	OKYO Pharma Announces Director Acquires Shares (GlobeNewswire)
07:00AM	OKYO Pharma Announces Chief Development Officer and Director Acquires Shares (GlobeNewswire)
Mar-18-26 09:02AM	OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial (Proactive)
07:00AM	OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain (GlobeNewswire)
Feb-23-26 04:15PM	Dow Jones sheds more than 800 points on Trump's latest tariff threat (Proactive)
03:30PM	Nasdaq, Dow Jones start the week lower as Trump resets tariffs (Proactive)
11:56AM	OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 (Proactive)
11:00AM	OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress (GlobeNewswire)
Feb-17-26 04:20PM	Nasdaq posts slim gain in calm trade as Wall Street inches up (Proactive)
03:49PM	Nasdaq climbs alongside Dow and S&P 500 in afternoon trading (Proactive)
12:56PM	OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain (Proactive)
Feb-13-26 08:50AM	OKYO Pharma prices $20M offering to fund late-stage eye drug trial (Proactive) -19.35%
Feb-12-26 10:20PM	OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares (GlobeNewswire) +11.28%
04:01PM	OKYO Pharma Announces Public Offering of Ordinary Shares (GlobeNewswire)
11:03AM	Loading…
Feb-11-26 11:03AM	OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering (Proactive) -6.70%
10:09AM	OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners (GlobeNewswire)
Feb-10-26 09:36AM	OKYO Pharma appoints Flavio Mantelli as chief medical officer (Proactive) +5.03%
08:00AM	OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer (GlobeNewswire)
Jan-30-26 11:30AM	OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting (GlobeNewswire)
Jan-28-26 01:18PM	OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial (Proactive)
07:40AM	OKYO Pharma Announces Successful Type C Meeting with the FDA (GlobeNewswire)
Jan-23-26 07:00AM	FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain (GlobeNewswire) -6.33%
Jan-05-26 07:00AM	OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer (GlobeNewswire) +7.62%
Dec-19-25 07:00AM	OKYO Pharma to Ring the Opening Bell at Nasdaq (GlobeNewswire) +8.56%
Dec-15-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) -8.25%
Dec-11-25 08:30AM	OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain (GlobeNewswire) +6.93%
Dec-03-25 07:00AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) -5.77%
Nov-21-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) +10.99%
Nov-18-25 08:30AM	OKYO Pharma to Present at OIS XV in San Diego (GlobeNewswire)
Oct-29-25 07:00AM	OKYO Pharma to Present at BIO-Europe 2025 in Vienna (GlobeNewswire) +6.67%
Oct-16-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire)
Sep-22-25 08:30AM	OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain (GlobeNewswire) +13.64%
Jul-17-25 09:00AM	OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
05:47AM	OKYO reports top-line data from neuropathic corneal pain therapy trial (Clinical Trials Arena)
Jul-16-25 09:21AM	OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire) +7.64%
Jun-11-25 10:05AM	Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited (ACCESSWIRE) +12.56%
08:30AM	OKYO Pharma to Present at the Bio International Convention (GlobeNewswire)
May-19-25 07:00AM	OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit (GlobeNewswire) +7.91%
May-01-25 07:00AM	FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
Apr-30-25 07:00AM	OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire)
Mar-31-25 08:00AM	OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod (GlobeNewswire) -5.93%
Mar-10-25 08:30AM	OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire)
Feb-12-25 07:00AM	OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod (GlobeNewswire)
Jan-31-25 07:00AM	OKYO Pharma Announces Chairman and CEO Acquire Shares (GlobeNewswire)
Jan-30-25 09:45AM	Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited (ACCESSWIRE)
Jan-29-25 08:00AM	OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter (GlobeNewswire)
Jan-23-25 07:11AM	Okyo Pharma receives $1.4M in non-dilutive financing (TipRanks)
Jan-22-25 07:00AM	OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding (GlobeNewswire)
Nov-26-24 07:00AM	OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference (GlobeNewswire)
Nov-15-24 09:00AM	MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-30-24 07:00AM	OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference (GlobeNewswire)
Oct-23-24 07:00AM	OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain (GlobeNewswire) +19.42%
Oct-17-24 07:27AM	OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug (TipRanks)
Oct-16-24 07:00AM	OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain (GlobeNewswire)
Sep-10-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire) +6.80%
Sep-05-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-27-24 07:00AM	OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease (GlobeNewswire) +14.72%
Aug-23-24 09:00AM	OKYO Pharma CEO Interview to Air on Bloomberg TV (GlobeNewswire)
09:00AM	OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-21-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-15-24 12:13PM	OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-06-24 07:00AM	OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use (GlobeNewswire) +5.26%
Jul-11-24 07:00AM	OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 (GlobeNewswire) +25.64%
Jul-10-24 07:00AM	OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease (GlobeNewswire)
Jun-26-24 10:29AM	Promising Developments from OKYO Pharma on Dry Eye Disease and Neuropathic Pain Treatment (News Direct)
May-24-24 03:07PM	OKYO Pharma Bullish Thesis (Insider Monkey) -11.06%
May-08-24 07:00AM	OKYO Pharma Announces Participation in May 2024 Investor Conferences (GlobeNewswire)
Apr-30-24 07:00AM	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) (GlobeNewswire)
Apr-08-24 07:00PM	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 (GlobeNewswire)
Apr-02-24 07:00AM	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery (GlobeNewswire)
Mar-22-24 07:00AM	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 (GlobeNewswire) -12.78%
Mar-21-24 07:00AM	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial (GlobeNewswire)
Mar-20-24 07:00AM	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event (GlobeNewswire) +20.00%
Feb-09-24 07:00AM	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain (GlobeNewswire) +19.58%
Jan-31-24 07:00AM	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board (GlobeNewswire)
Jan-08-24 07:00AM	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease (GlobeNewswire)
Jan-05-24 09:30AM	OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 (GlobeNewswire) +9.65%
Dec-04-23 07:00AM	OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit (GlobeNewswire)
Oct-31-23 07:00AM	OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction (GlobeNewswire)
Oct-09-23 07:00AM	OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP) (GlobeNewswire) -10.62%
Oct-05-23 07:00AM	OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ('DED') (GlobeNewswire) -9.09%
Sep-15-23 07:00AM	OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) +12.43%
Sep-14-23 09:15AM	OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) -10.61%

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

Chief Development Officer & DirectorDr. Gary S. Jacob Ph.D.

CEO & Executive DirectorMr. Robert J. Dempsey M.B.A.

FounderMr. Michael Paul Beck

Chief Financial OfficerMs. Keeren Shah

Chief Scientific OfficerDr. Rajkumar Patil Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OKYO

OKYO Pharma Limited

Upgrade your Finviz experience